Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderate to severe vasomotor symptoms associated with the menopause. Sold as Delestrogen. Every FDA application for this active ingredient: 1 branded and 7 generic.
As of Nov 15, 2026, FDA lists 8 applications for Estradiol Valerate (sold as Delestrogen), first approved Jul 15, 1954, with 0 new uses approved and 0 published complete response letters.
First approved: Jul 15, 1954
Applications: 8
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $2.3M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Estradiol Valerate
Part D
$2.2M
+21%
5,008
Delestrogen
Part D
$34K
-56%
104
Delestrogen
Part B
$25K
-30%
426
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
ESTRADIOL VALERATE 100 MG/5 ML: $22.96 per MLGeneric · +4% in a year
ESTRADIOL VALERATE 200 MG/5 ML: $37.82 per MLGeneric · -2% in a year
ESTRADIOL VALERATE 50 MG/5 ML: $18.37 per MLGeneric · +6% in a year
DELESTROGEN 100 MG/5 ML VIAL: $35.78 per MLBrand · 0% in a year
DELESTROGEN 50 MG/5 ML VIAL: $25.50 per MLBrand · +0% in a year
Clinical Trials
353 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Hikma